<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683368</url>
  </required_header>
  <id_info>
    <org_study_id>YPU105</org_study_id>
    <nct_id>NCT03683368</nct_id>
  </id_info>
  <brief_title>Extended Wear of a Steel and a Teflon Insulin Infusion Set</brief_title>
  <official_title>Extended Wear of a Steel and a Teflon Insulin Infusion Set</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ypsomed AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ypsomed AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross-over study to evaluate if insulin infusion sets can be used up to 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to infusion set failure due to an occlusion</measure>
    <time_frame>up to 7 days</time_frame>
    <description>an occlusion is defined by blood ketone concentration is &gt; or = 0.6 mmol/l with blood glucose (BG) concentration &gt;250 mg/dl, or BG concentration is &gt;250 mg/dl for more than 2 h and a subsequent correction bolus failed, or pump occlusion alarm that cannot be fixed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of early infusion set changes</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to early infusion set changes</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of early infusion set changes due to infusion site infection</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median infusion set wearing time</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily mean glucose</measure>
    <time_frame>day 1, 2, 3, 4, 5, 6, 7</time_frame>
    <description>Based on Continuous Glucose Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily mean glucose</measure>
    <time_frame>day 1, 2, 3, 4, 5, 6, 7</time_frame>
    <description>Based on self measured blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily insulin dose</measure>
    <time_frame>day 1, 2, 3, 4, 5, 6, 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>day 1, 2, 3, 4, 5, 6, 7</time_frame>
    <description>Coefficient of variation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Soft cannula first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized (50%) to the soft cannula infusion set for two weeks and then will be switched to the steel needle infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the soft cannula infusion set.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steel cannula first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized (50%) to the steel cannula infusion set for two weeks and then will be switched to the soft cannula infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the steel cannula infusion set.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YpsoPump Orbit soft</intervention_name>
    <description>Insulin infusion sets will be used for up to 7 days or until failure</description>
    <arm_group_label>Soft cannula first</arm_group_label>
    <arm_group_label>Steel cannula first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YpsoPump Orbit micro</intervention_name>
    <description>Insulin infusion sets will be used for up to 7 days or until failure</description>
    <arm_group_label>Soft cannula first</arm_group_label>
    <arm_group_label>Steel cannula first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of type 1 diabetes for at least 12 months

          -  Using an insulin pump for at least 12 months

          -  Age ≥18 years

          -  Hemoglobin A1c level less than or equal to 8.5%

          -  Willing to use mylife™ YpsoPump® system while they are participating in the study

          -  Willing to use NovoRapid® insulin while they are participating in the study

          -  An understanding of and willingness to follow the protocol and sign the informed
             consent

        Exclusion Criteria:

          -  Diabetic ketoacidosis in the past 3 months prior to enrollment

          -  Severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months
             prior to enrollment

          -  Urea, Creatinine, ALT more than three times the upper limit of normal, or
             thrombocytopenia (&lt;150 G/l)

          -  Female subjects: pregnancy, lactation period, lack of a negative pregnancy test
             (except in case of menopause, sterilization or hysterectomy), or unwilling to use an
             acceptable form of contraception during the study (for sexually active subjects of
             childbearing potential)

          -  Known severe tape reactions or allergies

          -  Known severe nickel allergies

          -  History of frequent catheter abscesses associated with pump therapy

          -  Serious acute or chronic disease besides diabetes mellitus or an anamnesis which
             might, in the opinion of the investigator, pose a risk to the subject, e.g. seizure
             disorder, adrenal disorder, dialysis for renal failure, cystic fibrosis, active
             infection

          -  Any incapacity or general condition that, in the opinion of the investigator, prevents
             adequate compliance with the study procedures, e.g. mental or visual incapacity,
             language barriers, alcohol or drug misuse

          -  Dependency from the sponsor or the clinical investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Freckmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Buhr, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Ypsomed AG, Burgdorf, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

